Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
London, 17 February 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced the strengthening of its team with the appointments of Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance. Both have spent their working careers in the biotech industry and bring extensive experience in their respective fields.
Victor Dillard, VP Corporate Development, began his life sciences career as a Venture Fellow at Flagship Pioneering in 2012, after which he founded Desktop Genetics, a genome editing bioinformatics and AI company. Victor led the company through multiple financing rounds, industrial partnerships, product launches and ultimate sale of the company in 2018. In 2019, Victor joined medical technology company Owkin where he supported the growth of the company through to Series B as VP, Head of Commercial Operations. Victor was nominated 30 Under 30 by Forbes, and MIT Innovator Under 35, Entrepreneur of the Year 2017 by the MIT Technology Review. He holds an MEng in chemical engineering from Imperial College London and an MPhil in Bioscience Enterprise from the University of Cambridge.
Lorna Peers, VP Finance, has held senior positions in PE backed and AiM listed biotechnology companies for the past 16 years, most recently as Chief Financial Officer for Censo Biotechnologies Ltd. Previous roles include Finance Director for Angel Biotechnology Holdings plc where she led several funding rounds and facility expansions; and Stem Cell Sciences plc, a dual listed (ASX) stem cell development company, subsequently sold to US based Stem Cells Inc. She holds a BA in Accounting and is a Fellow of the Association of Chartered Certified Accountants.
– Ends –
About Resolution
Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat chronic diseases characterised by life-threatening organ damage. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com